Literature DB >> 10510327

Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells.

G Baldassarre1, B Belletti, P Bruni, A Boccia, F Trapasso, F Pentimalli, M V Barone, G Chiappetta, M T Vento, S Spiezia, A Fusco, G Viglietto.   

Abstract

The majority of thyroid carcinomas maintain the expression of the cell growth suppressor p27, an inhibitor of cyclin-dependent kinase-2 (Cdk2). However, we find that 80% of p27-expressing tumors show an uncommon cytoplasmic localization of p27 protein, associated with high Cdk2 activity. To reproduce such a situation, a mutant p27 devoid of its COOH-terminal nuclear-localization signal was generated (p27-NLS). p27-NLS accumulates in the cytoplasm and fails to induce growth arrest in 2 different cell lines, indicating that cytoplasm-residing p27 is inactive as a growth inhibitor, presumably because it does not interact with nuclear Cdk2. Overexpression of cyclin D3 may account in part for p27 cytoplasmic localization. In thyroid tumors and cell lines, cyclin D3 expression was associated with cytoplasmic localization of p27. Moreover, expression of cyclin D3 in thyroid carcinoma cells induced cytoplasmic retention of cotransfected p27 and rescued p27-imposed growth arrest. Endogenous p27 also localized prevalently to the cytoplasm in normal thyrocytes engineered to stably overexpress cyclin D3 (PC-D3 cells). In these cells, cyclin D3 induced the formation of cytoplasmic p27-cyclin D3-Cdk complexes, which titrated p27 away from intranuclear complexes that contain cyclins A-E and Cdk2. Our results demonstrate a novel mechanism that may contribute to overcoming the p27 inhibitory threshold in transformed thyroid cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10510327      PMCID: PMC408550          DOI: 10.1172/JCI6443

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Subcellular and cell-cycle expression profiles of CDK-inhibitors in normal differentiating myeloid cells.

Authors:  B Yaroslavskiy; S Watkins; A D Donnenberg; T J Patton; R A Steinman
Journal:  Blood       Date:  1999-05-01       Impact factor: 22.113

2.  Key role of the cyclin-dependent kinase inhibitor p27kip1 for embryonal carcinoma cell survival and differentiation.

Authors:  G Baldassarre; M V Barone; B Belletti; C Sandomenico; P Bruni; S Spiezia; A Boccia; M T Vento; A Romano; S Pepe; A Fusco; G Viglietto
Journal:  Oncogene       Date:  1999-11-04       Impact factor: 9.867

Review 3.  A genetic model for colorectal tumorigenesis.

Authors:  E R Fearon; B Vogelstein
Journal:  Cell       Date:  1990-06-01       Impact factor: 41.582

4.  PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas.

Authors:  M Grieco; M Santoro; M T Berlingieri; R M Melillo; R Donghi; I Bongarzone; M A Pierotti; G Della Porta; A Fusco; G Vecchio
Journal:  Cell       Date:  1990-02-23       Impact factor: 41.582

Review 5.  Mammalian G1 cyclins.

Authors:  C J Sherr
Journal:  Cell       Date:  1993-06-18       Impact factor: 41.582

6.  Cloning and characterization of human cyclin D3, a cDNA closely related in sequence to the PRAD1/cyclin D1 proto-oncogene.

Authors:  T Motokura; K Keyomarsi; H M Kronenberg; A Arnold
Journal:  J Biol Chem       Date:  1992-10-05       Impact factor: 5.157

7.  Point mutations of ras oncogenes are an early event in thyroid tumorigenesis.

Authors:  H Namba; S A Rubin; J A Fagin
Journal:  Mol Endocrinol       Date:  1990-10

Review 8.  Molecular basis of epithelial tumorigenesis: the thyroid model.

Authors:  D Wynford-Thomas
Journal:  Crit Rev Oncog       Date:  1993

9.  High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.

Authors:  J A Fagin; K Matsuo; A Karmakar; D L Chen; S H Tang; H P Koeffler
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

10.  Regulation of the cell cycle by the cdk2 protein kinase in cultured human fibroblasts.

Authors:  M Pagano; R Pepperkok; J Lukas; V Baldin; W Ansorge; J Bartek; G Draetta
Journal:  J Cell Biol       Date:  1993-04       Impact factor: 10.539

View more
  39 in total

1.  Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells.

Authors:  M Kortylewski; P C Heinrich; M E Kauffmann; M Böhm; A MacKiewicz; I Behrmann
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

2.  Rat protein tyrosine phosphatase eta suppresses the neoplastic phenotype of retrovirally transformed thyroid cells through the stabilization of p27(Kip1).

Authors:  F Trapasso; R Iuliano; A Boccia; A Stella; R Visconti; P Bruni; G Baldassarre; M Santoro; G Viglietto; A Fusco
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

3.  Accumulation of p27(kip1) is associated with cyclin D3 overexpression in the oxyphilic (Hurthle cell) variant of follicular thyroid carcinoma.

Authors:  G Troncone; A Iaccarino; M Russo; E A Palmieri; M Volante; M Papotti; G Viglietto; L Palombini
Journal:  J Clin Pathol       Date:  2006-06-23       Impact factor: 3.411

4.  Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial-mesenchymal transition in human hepatocarcinoma.

Authors:  Sin-Ae Lee; Sung-Yul Lee; Ik-Hyun Cho; Min-A Oh; Eun-Sil Kang; Yong-Bae Kim; Woo Duck Seo; Suyong Choi; Ju-Ock Nam; Mimi Tamamori-Adachi; Shigetaka Kitajima; Sang-Kyu Ye; Semi Kim; Yoon-Jin Hwang; In-San Kim; Ki Hun Park; Jung Weon Lee
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

5.  Transcriptional downregulation of p27KIP1 through regulation of E2F function during LMP1-mediated transformation.

Authors:  David N Everly; Bernardo A Mainou; Nancy Raab-Traub
Journal:  J Virol       Date:  2009-10-14       Impact factor: 5.103

6.  Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization.

Authors:  Maria Letizia Motti; Daniela Califano; Giancarlo Troncone; Carmela De Marco; Ilenia Migliaccio; Emiliano Palmieri; Luciano Pezzullo; Lucio Palombini; Alfredo Fusco; Giuseppe Viglietto
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

Review 7.  p27 deregulation in breast cancer: prognostic significance and implications for therapy.

Authors:  A Alkarain; R Jordan; J Slingerland
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

8.  Cyclin-dependent kinase inhibitors, p16 and p27, demonstrate different expression patterns in thymoma and thymic carcinoma.

Authors:  Mutsuko Omatsu; Toshiaki Kunimura; Tetsuya Mikogami; Akira Shiokawa; Atsuko Masunaga; Tomoko Nagai; Akihiko Kitami; Takashi Suzuki; Mitsutaka Kadokura
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-06-18

Review 9.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Authors:  Robert C Smallridge; Laura A Marlow; John A Copland
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

10.  HMGA1a recognition candidate DNA sequences in humans.

Authors:  Takayuki Manabe; Taiichi Katayama; Masaya Tohyama
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.